Skip to main content

Table 4 Performances of imaging in detecting bone metastases of prostate cancer patients with first biochemical recurrence (patient-base analysis)

From: Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France

 SeSpPPVNPVAccuracyκ
NaF PET/CT
 On-site71% (5/7)92% (44/48)56% (5/9)96% (44/46)89% (49/55)0.96
 Central86% (6/7)94% (45/48)67% (6/9)98% (45/46)93% (51/55) 
FCH PET/CT
 On-site43% (3/7)100% (48/48)100% (3/3)92% (48/52)93% (51/55)0.86
 Central57% (4/7)98% (47/48)80% (4/5)94% (47/50)93% (51/55) 
DW-MRI
 On-site57% (4/7)83% (40/48)33% (4/12)93% (40/43)80% (40/55)0.59
 Central43% (3/7)94% (45/48)60% (3/5)90% (45/50)87% (48/55) 
  1. Se sensitivity, Sp specificity, PPV positive predictive value, NPV negative predictive value
  2. NaF18F-sodium fluoride, FCH18F-fluorocholine, DW-MRI diffusion-weighted whole-body magnetic resonance imaging
  3. Κ Cohen’s kappa coefficient